+

WO2001066572A3 - Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof - Google Patents

Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof Download PDF

Info

Publication number
WO2001066572A3
WO2001066572A3 PCT/EP2001/003445 EP0103445W WO0166572A3 WO 2001066572 A3 WO2001066572 A3 WO 2001066572A3 EP 0103445 W EP0103445 W EP 0103445W WO 0166572 A3 WO0166572 A3 WO 0166572A3
Authority
WO
WIPO (PCT)
Prior art keywords
coli
nature
group
strains
polynucleotides isolated
Prior art date
Application number
PCT/EP2001/003445
Other languages
French (fr)
Other versions
WO2001066572A9 (en
WO2001066572A2 (en
Inventor
Edouard Bingen
Stephane Bonacorsi
Olivier Clermont
Xavier Nassif
Colin Tinsley
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Edouard Bingen
Stephane Bonacorsi
Olivier Clermont
Xavier Nassif
Colin Tinsley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0003145A external-priority patent/FR2806096A1/en
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris, Edouard Bingen, Stephane Bonacorsi, Olivier Clermont, Xavier Nassif, Colin Tinsley filed Critical Inst Nat Sante Rech Med
Priority to JP2001565736A priority Critical patent/JP2004512817A/en
Priority to CA002402602A priority patent/CA2402602A1/en
Priority to EP01917119A priority patent/EP1328641A2/en
Publication of WO2001066572A2 publication Critical patent/WO2001066572A2/en
Publication of WO2001066572A9 publication Critical patent/WO2001066572A9/en
Priority to US10/238,075 priority patent/US20030148324A1/en
Publication of WO2001066572A3 publication Critical patent/WO2001066572A3/en
Priority to US12/025,365 priority patent/US20090298713A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to products which are of nature B2+ A-, isolated from E. coli, and to their biological applications, in particular their medical (therapeutic, vaccine and diagnostic) and biotechnological applications. In the present application, the expression 'of nature B2+ A-' is intended to mean presence at a frequency greater than 10 % among the E. coli strains of group B2 of the ECOR collection, and at a frequency of less than 10 % among the strains of group A of the same collection. A phylogenic determination method which makes it possible to rapidly and easily distinguish the groups A, B1, B2 and D of the E. coli species with more than 99 % precision is in particular described.
PCT/EP2001/003445 2000-03-10 2001-03-12 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof WO2001066572A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001565736A JP2004512817A (en) 2000-03-10 2001-03-12 B2 / D + A-type polynucleotides isolated from Escherichia coli and biological uses of these polynucleotides and their polypeptides
CA002402602A CA2402602A1 (en) 2000-03-10 2001-03-12 Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides
EP01917119A EP1328641A2 (en) 2000-03-10 2001-03-12 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
US10/238,075 US20030148324A1 (en) 2001-02-02 2002-09-10 Polynucleotides which are of nature B2/D+ A- and which are isolated from E. coli, and biological uses of these polynucleotides and of their polypeptides
US12/025,365 US20090298713A1 (en) 2000-03-10 2008-02-04 Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0003145A FR2806096A1 (en) 2000-03-10 2000-03-10 B2 + A-ISOLATED PRODUCTS FROM E.COLI, AND THEIR BIOLOGICAL APPLICATIONS
FR00/03145 2000-03-10
FR01/01449 2001-02-02
FR0101449 2001-02-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/238,075 Continuation-In-Part US20030148324A1 (en) 2000-03-10 2002-09-10 Polynucleotides which are of nature B2/D+ A- and which are isolated from E. coli, and biological uses of these polynucleotides and of their polypeptides

Publications (3)

Publication Number Publication Date
WO2001066572A2 WO2001066572A2 (en) 2001-09-13
WO2001066572A9 WO2001066572A9 (en) 2002-08-15
WO2001066572A3 true WO2001066572A3 (en) 2003-05-01

Family

ID=26212251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003445 WO2001066572A2 (en) 2000-03-10 2001-03-12 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof

Country Status (4)

Country Link
EP (1) EP1328641A2 (en)
JP (1) JP2004512817A (en)
CA (1) CA2402602A1 (en)
WO (1) WO2001066572A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1342784A1 (en) * 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
HUE030881T2 (en) * 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
US8277798B2 (en) * 2006-05-10 2012-10-02 Institut National De La Recherche Agronomique Use of cells containing a specific DNA molecule as cytopathic agents to inhibit the proliferation of cells
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
ITMI20090946A1 (en) 2009-05-28 2010-11-29 Novartis Ag EXPRESSION OF RECOMBINANT PROTEINS
PT2464658E (en) 2009-07-16 2015-01-14 Novartis Ag Detoxified escherichia coli immunogens
EP2298798B1 (en) * 2009-09-10 2012-05-09 Freie Universität Berlin Identification and characterization of a novel avian pathogenic E. coli (APEC) fimbrial adhesin
EP2736922B1 (en) 2011-07-28 2017-11-01 Universiteit Gent Prevention of salmonella recrudescense
GB2554742A (en) * 2016-10-07 2018-04-11 Bhongir Ravi Treatment
US12290563B2 (en) 2021-04-01 2025-05-06 Janssen Pharmaceuticals, Inc. Production of E. coli 018 bioconjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078716A1 (en) * 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
EP0666271A1 (en) * 1994-02-04 1995-08-09 Industrial Farmaceutica Y De Especialidades, S.A. Type 1 and type P fimbriae-adhesins isolated from novel E. coli strains, process for their preparation and uses thereof
WO1996030043A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
WO1998022575A2 (en) * 1996-11-22 1998-05-28 Human Genome Sciences, Inc. Nucleotide sequence of escherichia coli pathogenicity islands

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078716A1 (en) * 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
EP0666271A1 (en) * 1994-02-04 1995-08-09 Industrial Farmaceutica Y De Especialidades, S.A. Type 1 and type P fimbriae-adhesins isolated from novel E. coli strains, process for their preparation and uses thereof
WO1996030043A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
WO1998022575A2 (en) * 1996-11-22 1998-05-28 Human Genome Sciences, Inc. Nucleotide sequence of escherichia coli pathogenicity islands

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BINGEN E ET AL: "GENOTYPING MAY PROVIDE RAPID IDENTIFICATION OF ESCHERICHIA COLI K1 ORGANISMS THAT CAUSE NEONATAL MENINGITIS", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 22, no. 1, January 1996 (1996-01-01), pages 152 - 156, XP001058202, ISSN: 1058-4838 *
BINGEN E, PICARD B, BRAHIMI N, MATHY S, DESJARDINS P, ELION J, DENAMUR E: "Phylogenetic analysis of Escherichia coli strains causing neonatal meningitis suggests horizontal gene transfer from a predominant pool of highly virulent B2 group strains.", JOURNAL OF INFECTIOUS DISEASES, vol. 177, no. 3, March 1998 (1998-03-01), pages 642 - 650, XP000980536 *
BONACORSI S.P.P., ET AL.: "Identification of regions of the Escherichia coli chromosome specific for neonatal meningitis-associated strains", INFECTION AND IMMUNITY., vol. 68, no. 4, April 2000 (2000-04-01), WASHINGTON US, pages 2096 - 2101, XP000979002 *
BROWN PK, CURTISS R 3RD.: "Unique chromosomal regions associated with virulence of an avian pathogenic Escherichia coli strain.", PROC NATL ACAD SCI U S A 1996 OCT 1;93(20):11149-54, XP002194780 *
CLERMONT O, BONACORSI S, BINGEN E: "Rapid and simple determination of the Escherichia coli phylogenetic group.", APPL ENVIRON MICROBIOL, vol. 66, no. 10, October 2000 (2000-10-01), pages 4555 - 4558, XP000980563 *
CLERMONT O, CORDEVANT C, BONACORSI S, MARECAT A, LANGE M, BINGEN E.: "AUTOMATED RIBOTYPING PROVIDES RAPID PHYLOGENETIC SUBGROUP AFFILIATION OF CLINICAL EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLISTRAINS", JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 39, no. 12, December 2001 (2001-12-01), pages 4549 - 4553, XP001058236, ISSN: 0095-1137 *
E. FIDELMA BOYD AND DANIEL L. HARTL: "Chromosomal Regions Specific to Pathogenic Isolates of Escherichia coli Have a Phylogenetically Clustered Distribution", J BACTERIOL, MARCH 1998, P. 1159-1165, VOL. 180, NO. 5, XP002133065 *
HURTADO, A. E& RODRIGUEZ-VALERA F.: "Accessory DNA in the genomes of representatives of the Escherichia coli reference collection", J. BACTERIOLOGY, vol. 181, no. 8, April 1999 (1999-04-01), pages 2548 - 2554, XP002210757 *
JOHNSON J J ET AL: "EXTENDED VIRULENCE GENOTYPES OF ESCHERICHIA COLI STRAINS FROM PATIENTS WITH UROSEPSIS IN RELATION TO PHYLOGENY AND HOST COMPROMISE", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 181, January 2000 (2000-01-01), pages 261 - 272, XP001058205, ISSN: 0022-1899 *
JOHNSON J R ET AL: "IMPROVED REPETITIVE-ELEMENT PCR FINGERPRINTING FOR RESOLVING PATHOGENIC AND NONPATHOGENIC PHYLOGENETIC GROUPS WITHIN ESCHERICHIACOLI", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 7, no. 2, 1 March 2000 (2000-03-01), pages 265 - 273, XP000980486, ISSN: 1071-412X *
JOHNSON J.R. ET AL.: "Diversity of hemagglutination phenotypes among P-fimbriated wild-type strains of Escherichia coli in relation to papG allele repertoire", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 5, no. 2, March 1998 (1998-03-01), pages 160 - 170, XP002210759 *
KUHNERT P, BOERLIN P, FREY J.: "Target genes for virulence assessment of Escherichia coli isolates from water, food and the environment.", FEMS MICROBIOL REV., vol. 24, no. 1, January 2000 (2000-01-01), pages 107 - 117, XP000980001 *
LISITSYN N ET AL: "CLONING THE DIFFERENCES BETWEEN TWO COMPLEX GENOMES", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 259, 12 February 1993 (1993-02-12), pages 946 - 951, XP000601302, ISSN: 0036-8075 *
MILLS M, PAYNE SM.: "Genetics and regulation of heme iron transport in Shigella dysenteriae and detection of an analogous system in Escherichia coli O157:H7.", J BACTERIOL. 1995 JUN;177(11):3004-9., XP002210758 *
PAQUE, R.E. ET AL.: "Polyclonal anti-idiotypic antibodies exhibit antigenic mimicry of limited type 1 fimbrial proteins of Escherichia coli", INFECTION AND IMMUNITY, vol. 58, no. 3, March 1990 (1990-03-01), pages 680 - 686, XP001072474 *
PICARD B. ET AL.: "The Link between Phylogeny and Virulence in Escherichia coli Extraintestinal Infection", INFECTION AND IMMUNITY, FEBRUARY 1999, P. 546-553, VOL. 67, NO. 2, XP000980017 *
RODE C K ET AL: "TYPE-SPECIFIC CONTRIBUTIONS TO CHROMOSOME SIZE DIFFERENCES IN ESCHERICHIA COLI", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 19, no. 1, January 1999 (1999-01-01), pages 230 - 236, XP000979058, ISSN: 0019-9567 *
SH HUANG, C WASS, Q FU, NV PRASADARAO, M STINS AND KS KIM: "Escherichia coli invasion of brain microvascular endothelial cells in vitro and in vivo: molecular cloning and characterization of invasion gene ibe10", INFECTION AND IMMUNITY., vol. 63, no. 11, November 1995 (1995-11-01), WASHINGTON US, pages 4470 - 4475, XP000980542 *
TINSLEY C R ET AL: "ANALYSIS OF THE GENETIC DIFFERENCES BETWEEN NEISSERIA MENINGITIDIS AND NEISSERIA GONORRHOEAE: TWO CLOSELY RELATED BACTERIA EXPRESSING TWO DIFFERENT PATHOGENICITIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 20, 1 October 1996 (1996-10-01), pages 11109 - 1114, XP002028346, ISSN: 0027-8424 *
WYCKOFF, E.E. ET AL.: "Structure of the Shigella dysenteriae haem transport locus and its phylogenetic distribution in enteric bacteria", MOLECULAR MICROBIOLOGY, vol. 28, no. 6, June 1998 (1998-06-01), pages 1139 - 1152, XP008006993 *

Also Published As

Publication number Publication date
WO2001066572A9 (en) 2002-08-15
WO2001066572A2 (en) 2001-09-13
EP1328641A2 (en) 2003-07-23
JP2004512817A (en) 2004-04-30
CA2402602A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
WO2001066572A3 (en) Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
WO2001012659A3 (en) Human dna sequences
WO1995025171A3 (en) Dna sequences for matrix metalloproteases, their production and use
WO1998050554A3 (en) Enterococcus faecalis polynucleotides and polypeptides
WO2005049642A3 (en) Genome of legionella pneumophila paris and lens strain-diagnostic and epidemiological applications
EP2280030A3 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP2192128A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2003086308A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2001023606A3 (en) Nucleic acid molecules for detecting bacteria and phylogenetic units of bacteria
WO1999049881A3 (en) Application of hsp70 proteins
WO1998049311A3 (en) Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
WO2002040668A3 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
EP1757696A3 (en) Group B streptococcus proteins, and their use
WO1997028812A3 (en) Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre)
Dumetz et al. Analysis of the Flavobacterium psychrophilum outer-membrane subproteome and identification of new antigenic targets for vaccine by immunomics
WO2002070741A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
EP1574579A3 (en) Outer surface proteins, their genes, and their use
WO2002014361A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
Hänninen et al. Pulsed‐field gel electrophoresis in the study of mesophilic and psychrophilic Aeromonas spp.
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
EP1627927A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
WO2004072263A3 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
AU2002357562A1 (en) Process of extracting small molecular ingredients from biological materials under super high pressure
EP2022797A3 (en) Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGE 81/230, DRAWINGS, ADDED; PAGES 219/276, 221/276, 222/276, 225/276 AND 226/276, SEQUENCE LISTING, ADDED

WWE Wipo information: entry into national phase

Ref document number: 2001917119

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 565736

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10238075

Country of ref document: US

Ref document number: 2402602

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001917119

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载